Urogen Pharma (NASDAQ:URGN – Free Report) – Equities researchers at HC Wainwright increased their Q3 2027 earnings estimates for shares of Urogen Pharma in a research note issued on Monday, May 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.28 per share for the quarter, up from their prior forecast of $0.27. HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q4 2027 earnings at $0.49 EPS and FY2027 earnings at $0.50 EPS.
Several other equities research analysts have also recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Tuesday, March 31st. Oppenheimer upped their price objective on shares of Urogen Pharma from $34.00 to $40.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma in a research report on Monday. They set a “buy” rating and a $43.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $36.67.
Urogen Pharma Stock Up 6.6%
URGN opened at $31.33 on Tuesday. The stock’s fifty day moving average is $20.97 and its two-hundred day moving average is $21.74. The company has a market capitalization of $1.53 billion, a P/E ratio of -11.39 and a beta of 1.58. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $32.37.
Urogen Pharma (NASDAQ:URGN – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million.
Hedge Funds Weigh In On Urogen Pharma
Several institutional investors and hedge funds have recently added to or reduced their stakes in URGN. Osaic Holdings Inc. lifted its position in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after acquiring an additional 486 shares in the last quarter. State of Wyoming bought a new position in shares of Urogen Pharma during the 3rd quarter worth approximately $66,000. Russell Investments Group Ltd. lifted its position in Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after acquiring an additional 3,125 shares during the last quarter. Finally, Strs Ohio acquired a new stake in Urogen Pharma in the third quarter valued at approximately $76,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.
About Urogen Pharma
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
See Also
- Five stocks we like better than Urogen Pharma
- Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It
- TMC Forges a New EV Supply Chain at the Bottom of the Sea
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
